Skip to main content
IDYA
NASDAQ Life Sciences

IDEAYA Expands Roche Tie-Up: Genentech to Test IDE892 With KRAS G12D Inhibitor in Pancreatic Cancer

Tom Rudovsky · Reported by PR Newswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$37.93
Mkt Cap
$3.66B
52W Low
$23.23
52W High
$40.58
52W Position info
63% above low
Off High info
6.5% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

IDYA sits 63% above its 52-week low of $23.23.

Summary

IDEAYA announced a clinical collaboration with Genentech (Roche Group) to evaluate its PRMT5 inhibitor IDE892 in combination with Genentech's KRAS G12D inhibitor GDC-7035 (RG6620) in MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma. Genentech will sponsor the trial, with IDEAYA supplying IDE892. This expands the existing Roche relationship beyond the June 3 collaboration (which paired IDE892 with Roche's RG6505 in MTAP-deleted RAS-mutant PDAC). The new combination targets a patient population where MTAP deletions and KRAS G12D mutations co-occur in up to ~15% of PDAC cases, with no approved targeted therapies. IDEAYA retains commercial rights to IDE892. The company plans to initiate a separate Phase 1 cohort with RG6505 in 2H 2026. This adds a second KRAS-directed combination partner for IDE892, strengthening the pipeline narrative ahead of the darovasertib NDA submission expected in H2 2026.

At the time of this announcement, IDYA was trading at $37.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $23.23 to $40.58. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.


Price Chart

Share this article

Copied!

IDYA - Latest Insights

IDYA
Nov 03, 2026, 4:00 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $31.36
Real-time Price: $26.49 info
Change: -$4.87 (-16%) info
Market Cap: $2.561B info
IDYA
Nov 03, 2026, 6:00 AM EST
Source: PR Newswire
Importance Score:
7
Price at Filing: $31.64
Real-time Price: $26.49 info
Change: -$5.15 (-16%) info
Market Cap: $2.561B info
IDYA
Oct 19, 2026, 7:08 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $33.50
Real-time Price: $26.49 info
Change: -$7.01 (-21%) info
Market Cap: $2.561B info
IDYA
Aug 04, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $36.11
Real-time Price: $26.49 info
Change: -$9.62 (-27%) info
Market Cap: $2.561B info
IDYA
Aug 04, 2026, 6:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $35.40
Real-time Price: $26.49 info
Change: -$8.91 (-25%) info
Market Cap: $2.561B info